SCHERING-PLOUGH's INTRON A U.S. SALES WILL DOUBLE IN 1991 WITH HEPATITIS C INDICATION, COMPANY PREDICTS; OTC GYNE-LOTRIMIN SALES IN U.S. TOP $ 100 MIL.